Seveno Capital invests in PointFit, a Hong Kong startup revolutionizing health monitoring with a skin patch wearable that tracks biomarkers in real-time.
Seveno Capital, a global venture platform, has made a strategic investment in PointFit, a Hong Kong-based company that is developing innovative wearable technology. This investment signals growing confidence in the future of health monitoring, moving beyond basic fitness trackers to advanced devices that provide detailed insights into the human body.
PointFit is creating a skin patch wearable designed to monitor biomarkers in real-time through sweat. This allows for non-invasive and continuous tracking of key health indicators. The company's technology represents a significant shift from traditional wearables that primarily measure heart rate and motion, offering a more direct and comprehensive view of an individual's physiology.
The company's first product focuses on Continuous Lactate Monitoring (CLM), which helps users understand their fatigue levels, endurance capacity, and recovery progress. This is particularly valuable for athletes and individuals interested in optimizing their physical performance. Traditionally, biomarker data has only been accessible through invasive procedures and controlled environments.
Seveno Capital's investment values PointFit at US $10 million. This financial backing will help PointFit accelerate its commercialization efforts and expand its reach into international markets.
This investment also marks Seveno Capital's first deal led by Jean-Baptiste Roy, who recently joined the firm as a Partner. Roy's expertise in sports technology and human performance investing will be instrumental in guiding PointFit's growth and development.
PointFit's initial focus is on endurance-related biomarkers like lactate, electrolytes, and sweat rate. However, the company plans to expand its platform to track multiple diagnostic biomarkers, opening up possibilities for applications in performance enhancement, metabolic health management, and longevity-focused care.
The wearable market is predicted to significantly expand, reaching US$200 billion by 2030. This growth is driven by increasing consumer demand for advanced health data and personalized insights. PointFit is strategically positioned to capture a substantial portion of this market, specifically targeting endurance athletes seeking real-time physiological optimization.
PointFit has already gained recognition within the sports industry, with successful demonstrations carried out with global sports federations, teams, and fitness equipment manufacturers. The company's presence in North America has also been strengthened through showcases in Indiana and participation in the Startup World Cup Finale in Silicon Valley.
The company's innovative technology was further highlighted at CES 2026 in Las Vegas, where PointFit received a CES Innovation Award in Digital Health.
Seveno Capital views PointFit as a key player in the evolving global fitness and wellness landscape, with Asian innovation increasingly shaping the industry. The investment in PointFit aligns with Seveno Capital's strategy of supporting globally scalable healthspan platforms emerging from Asia.
Seveno Capital's new Hong Kong office will serve as a base for identifying and backing cutting-edge technologies in performance, prevention, and longevity. This investment in PointFit is the first transaction since the opening of the Hong Kong office.
